Cargando…

Fibroblast Growth Factor Receptor (FGFR) Signaling in GIST and Soft Tissue Sarcomas

Sarcomas are a heterogeneous group of rare malignancies originating from mesenchymal tissues with limited therapeutic options. Recently, alterations in components of the fibroblast growth factor receptor (FGFR) signaling pathway have been identified in a range of different sarcoma subtypes, most not...

Descripción completa

Detalles Bibliográficos
Autores principales:	Napolitano, Andrea, Ostler, Alexandra E., Jones, Robin L., Huang, Paul H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8235236/ https://www.ncbi.nlm.nih.gov/pubmed/34204560 http://dx.doi.org/10.3390/cells10061533

Ejemplares similares

2018 ESMO Sarcoma and GIST Symposium: ‘take-home messages’ in soft tissue sarcoma
por: Frezza, Anna Maria, et al.
Publicado: (2018)

Negative Regulation of FGFR (Fibroblast Growth Factor Receptor) Signaling
por: Szybowska, Patrycja, et al.
Publicado: (2021)

Adherence to Guidelines for Adult (Non-GIST) Soft Tissue Sarcoma in the Netherlands: A Plea for Dedicated Sarcoma Centers
por: Hoekstra, Harald J., et al.
Publicado: (2017)

Olaratumab: a platelet-derived growth factor receptor-α-blocking antibody for the treatment of soft tissue sarcoma
por: Pender, Alexandra, et al.
Publicado: (2017)

Molecular targeted therapies in non-GIST soft tissue sarcomas: what the radiologist needs to know
por: Tirumani, Sree Harsha, et al.
Publicado: (2013)

The Extracellular Matrix in Soft Tissue Sarcomas: Pathobiology and Cellular Signalling
por: Pankova, Valeriya, et al.
Publicado: (2021)

Pazopanib in advanced soft tissue sarcomas
por: Lee, Alex T. J., et al.
Publicado: (2019)

Efficacy of Eribulin in Soft Tissue Sarcomas
por: Phillips, Edward, et al.
Publicado: (2022)

Trabectedin in Soft Tissue Sarcomas
por: Petek, Bradley J., et al.
Publicado: (2015)

Highlights in soft tissue sarcomas and gastrointestinal stromal tumours (GIST) trials reported at ASCO 2017 Annual Meeting
por: Frezza, Anna Maria, et al.
Publicado: (2017)

Targeting the Fibroblast Growth Factor Receptor (FGFR) Family in Lung Cancer
por: Pacini, Laura, et al.
Publicado: (2021)

Fibroblast Growth Factor Receptor (FGFR) Inhibitors in Urothelial Cancer
por: Garje, Rohan, et al.
Publicado: (2020)

The cost-saving effect of centralized histological reviews with soft tissue and visceral sarcomas, GIST, and desmoid tumors: The experiences of the pathologists of the French Sarcoma Group
por: Perrier, Lionel, et al.
Publicado: (2018)

Predictive and prognostic transcriptomic biomarkers in soft tissue sarcomas
por: Merry, Eve, et al.
Publicado: (2021)

Inhibition of AKT-Signaling Sensitizes Soft Tissue Sarcomas (STS) and Gastrointestinal Stromal Tumors (GIST) to Doxorubicin via Targeting of Homology-Mediated DNA Repair
por: Boichuk, Sergei, et al.
Publicado: (2020)

Platelet-Derived Growth Factors in Non-GIST Soft-Tissue Sarcomas Identify a Subgroup of Patients with Wide Resection Margins and Poor Disease-Specific Survival
por: Kilvaer, Thomas Karsten, et al.
Publicado: (2010)

Phase III Soft Tissue Sarcoma Trials: Success or Failure?
por: Lee, Alexander T. J., et al.
Publicado: (2017)

PDGFRα inhibition in soft-tissue sarcomas: Have we gotten it all wrong?
por: Napolitano, Andrea, et al.
Publicado: (2019)

Significance of Phosphorylated Epidermal Growth Factor Receptor and Its Signal Transducers in Human Soft Tissue Sarcoma
por: Yang, Jia-Lin, et al.
Publicado: (2017)

Notch signaling in pediatric soft tissue sarcomas
por: Rota, Rossella, et al.
Publicado: (2012)

Current Status and Future Directions of Immunotherapies in Soft Tissue Sarcomas
por: Kerrison, William G. J., et al.
Publicado: (2022)

GEIS 2013 guidelines for gastrointestinal sarcomas (GIST)
por: Poveda, Andrés, et al.
Publicado: (2014)

Signaling by Fibroblast Growth Factors (Fgf) and Fibroblast Growth Factor Receptor 2 (Fgfr2)–Activating Mutations Blocks Mineralization and Induces Apoptosis in Osteoblasts
por: Mansukhani, Alka, et al.
Publicado: (2000)

Advances in the treatment of soft tissue sarcoma: focus on eribulin
por: Koliou, Panagiotis, et al.
Publicado: (2018)

Targeted treatment for advanced soft tissue sarcoma: profile of pazopanib
por: Rajendra, Rajeev, et al.
Publicado: (2013)

Efficacy and safety of eribulin mesylate in advanced soft tissue sarcomas
por: Noujaim, Jonathan, et al.
Publicado: (2016)

Virtual Biopsy in Soft Tissue Sarcoma. How Close Are We?
por: Arthur, Amani, et al.
Publicado: (2022)

Soft-tissue Sarcomas
por: Vodanovich, Domagoj Ante, et al.
Publicado: (2018)

Expression of basic fibroblast growth factor, FGFR1 and FGFR2 in normal and malignant human breast, and comparison with other normal tissues.
por: Luqmani, Y. A., et al.
Publicado: (1992)

The proteomic landscape of soft tissue sarcomas
por: Burns, Jessica, et al.
Publicado: (2023)

Fibroblast Growth Factor Receptor 2 (FGFR2) Mutation Related Syndromic Craniosynostosis
por: Azoury, Saïd C., et al.
Publicado: (2017)

Role of Fibroblast Growth Factor Receptor 2 (FGFR2) in Corneal Stromal Thinning
por: Joseph, Roy, et al.
Publicado: (2023)

Secondary KIT mutations: the GIST of drug resistance and sensitivity
por: Napolitano, Andrea, et al.
Publicado: (2019)

Characterization of FGFR signaling pathway as therapeutic targets for sarcoma patients
por: Zhou, Wen-Ya, et al.
Publicado: (2016)

SEOM Clinical Guideline for gastrointestinal sarcomas (GIST) (2016)
por: Poveda, A., et al.
Publicado: (2016)

Novel mutation detection of fibroblast growth factor receptor 1 (FGFR1) gene, FGFR2IIIa, FGFR2IIIb, FGFR2IIIc, FGFR3, FGFR4 gene for craniosynostosis: A prospective study in Asian Indian patient
por: Barik, Mayadhar, et al.
Publicado: (2015)

Impact of fibroblast growth factor receptor 1 (FGFR1) amplification on the prognosis of breast cancer patients
por: Erber, Ramona, et al.
Publicado: (2020)

Spontaneous cutaneous soft tissue sarcoma with differentiation into fibroblasts in a Sprague-Dawley rat
por: Ogawa, Takashi, et al.
Publicado: (2016)

Fibroblast growth factor receptor 3 (FGFR3) aberrations in muscle-invasive urothelial carcinoma
por: Kim, Young Saing, et al.
Publicado: (2018)

Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application
por: Chae, Young Kwang, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_hthpqc8oorq73m562jiae6f5on